1. Academic Validation
  2. Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma

Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma

  • Mol Cancer Res. 2019 Apr;17(4):963-973. doi: 10.1158/1541-7786.MCR-18-0574.
Dominic Lapadula 1 Eduardo Farias 2 3 4 Clinita E Randolph 1 Timothy J Purwin 5 Dougan McGrath 1 Thomas H Charpentier 1 Lihong Zhang 6 Shihua Wu 6 Mizue Terai 7 Takami Sato 7 Gregory G Tall 8 Naiming Zhou 6 Philip B Wedegaertner 1 Andrew E Aplin 5 Julio Aguirre-Ghiso 2 3 4 Jeffrey L Benovic 9
Affiliations

Affiliations

  • 1 Department of Biochemistry and Molecular Biology, Cancer Cell Biology and Signaling Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • 2 Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
  • 3 Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • 4 Department of Oncological Sciences and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • 5 Department of Cancer Biology, Cancer Cell Biology and Signaling Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • 6 College of Life Sciences, Zhejiang University, Hangzhou, P.R. China.
  • 7 Department of Medical Oncology, Sidney Kimmel Medical College, Cancer Cell Biology and Signaling Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • 8 Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, Michigan.
  • 9 Department of Biochemistry and Molecular Biology, Cancer Cell Biology and Signaling Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. jeffrey.benovic@jefferson.edu.
Abstract

Uveal melanoma is the most common intraocular tumor in adults and often metastasizes to the liver, leaving patients with few options. Recurrent activating mutations in the G proteins, Gαq and Gα11, are observed in approximately 93% of all uveal melanomas. Although therapeutic intervention of downstream Gαq/11 targets has been unsuccessful in treating uveal melanoma, we have found that the Gαq/11 inhibitor, FR900359 (FR), effectively inhibits oncogenic Gαq/11 signaling in uveal melanoma cells expressing either mutant Gαq or Gα11. Inhibition of oncogenic Gαq/11 by FR results in cell-cycle arrest and induction of Apoptosis. Furthermore, colony formation is prevented by FR treatment of uveal melanoma cells in 3D-cell culture, providing promise for future in vivo studies. This suggests direct inhibition of activating Gαq/11 mutants may be a potential means of treating uveal melanoma. IMPLICATIONS: Oncogenic Gαq/11 inhibition by FR900359 may be a potential treatment option for those with uveal melanoma.

Figures
Products